You are here

Home ยป Company Details

VENTRIX INCORPORATED

Company Information
Address
3231 HILL ST
SAN DIEGO, CA 92106-2412
United States
Information

UEI: GZK6V6LL3SM8

# of Employees: 0
Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No

Award Charts




Award Listing

  • Record 1 TO 6

  1. Pivotal Preclinical Studies of Novel Infusible ECM for Treating Acute MI

    Amount: $552,109.00

    Summary Heart failure post-myocardial infarction (MI) continues to be the leading cause of death in the U.S. Each year it is estimated that ~550K Americans will have a new MI, and ~200K will have a re ...

    SBIRPhase II2023Department of Health and Human Services National Institutes of Health

  2. New infusible ECM hydrogel for treating acute myocardial infarction

    Amount: $791,543.00

    Summary Heart failure post-myocardial infarction (MI) continues to be the leading cause of death in the U.S. Each year it is estimated that ~550K Americans will have a new MI, and ~200K will have a re ...

    SBIRPhase I2020Department of Health and Human Services National Institutes of Health

  3. Phase IIB: Percutaneous deliverable biomaterial for treating myocardial infarction

    Amount: $1,026,130.00

    DESCRIPTION provided by applicant Heart failure following a myocardial infarction MI continues to remain a leading killer in the western world In the United States the estimated annual incidenc ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health

  4. Phase II: Percutaneous deliverable biomaterial for treating myocardial infarction

    Amount: $2,059,825.00

    DESCRIPTION (provided by applicant): Heart failure following a myocardial infarction (MI) continues to remain a leading killer in the western world. In the United States, the estimated annual incidenc ...

    SBIRPhase II2013Department of Health and Human Services National Institutes of Health

  5. Percutaneous deliverable biomaterial for treating myocardial infarction

    Amount: $496,930.00

    DESCRIPTION (provided by applicant): Heart failure following a myocardial infarction (MI) continues to remain a leading killer in the western world. In the United States, the estimated annual incidenc ...

    SBIRPhase I2011Department of Health and Human Services National Institutes of Health

  6. SBIR Phase I:Feasibility of a minimally-invasive biomaterial therapy for heart failure

    Amount: $180,000.00

    This Small Business Innovation Research (SBIR) Phase I project will test the feasibility of delivering a biomaterial treatment for myocardial infarction (MI) and heart failure via catheter, thereby pa ...

    SBIRPhase I2010National Science Foundation
US Flag An Official Website of the United States Government